

**PHS PUBLIC ACCESS**

Author manuscript

Cell Host Microbe. Author manuscript; available in PMC 2018 December 13.

Published in final edited form as:

Cell Host Microbe. 2017 December 13; 22(6): 766–776.e4. doi:10.1016/j.chom.2017.11.005.**Inhibiting the *Plasmodium* eIF2 α kinase PK4 prevents artemisinin-induced latency****Min Zhang^{1,2,3,*,#}, Julio Gallego-Delgado⁴, Cristina Fernandez-Arias³, Norman C. Waters⁵, Ana Rodriguez⁴, Moriya Tsuji³, Ronald C. Wek⁶, Victor Nussenzweig², and William J. Sullivan Jr.^{1,*}**¹Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA²Department of Pathology, New York University School of Medicine, New York, New York, USA³HIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, New York, USA⁴Division of Parasitology, Department of Microbiology, New York University School of Medicine, New York, New York, USA⁵Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA⁶Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA**Summary**

Artemisinin and its derivatives (ARTs) are frontline antimalarial drugs. However, ART monotherapy is associated with a high frequency of recrudescence, resulting in treatment failure. A subset of parasites is thought to undergo ART-induced latency, but the mechanisms remain unknown. Here we report that ART treatment results in phosphorylation of the parasite eukaryotic initiation factor-2 α (eIF2 α), leading to repression of general translation and latency induction. Enhanced phosphorylated eIF2 α correlates with high rates of recrudescence following ART, and inhibiting eIF2 α dephosphorylation renders parasites less sensitive to ART treatment. ART-induced eIF2 α phosphorylation is mediated by the *Plasmodium* eIF2 α kinase, PK4. Overexpression of a PK4 dominant-negative or pharmacological inhibition of PK4 blocks parasites from entering latency and abolishes recrudescence after ART treatment of infected mice. These

*Correspondence: zhanmin@iu.edu (M.Z.), wjsulliv@iu.edu (W.J.S.).

#Lead contact

Author Contributions


M.Z. contributed design the study, performed the experiments, and wrote the manuscript. J.G. and A.R. contributed *P. falciparum* culture. C.F and M.T. contributed FACS. N.C.W. contributed discussion. R.C.W. contributed discussion and wrote the manuscript. V. N. contributed to the study design and wrote the manuscript. W.J.S. contributed reagent supply, discussion and wrote the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

results show that translational control underlies ART-induced latency and that interference with this stress response may resolve the clinical problem of recrudescence infection.

eTOC paragraph

The antimalarial drug artemisinin is associated with a high frequency of recrudescence infection. Zhang et al. identified that artemisinin induces latency through *Plasmodium* eukaryotic initiation factor 2 α (eIF2 α) phosphorylation. Inhibiting the *Plasmodium* eIF2 α kinase PK4 blocks parasites from entering latency and abolishes recrudescence after artemisinin therapy.



Keywords

Plasmodium; artemisinin; recrudescence; eIF2 α ; PK4; resistance

Introduction

The malaria parasite *Plasmodium* spp. was estimated to cause 212 million new cases and over 0.4 million deaths in 2015 (World Health Organization., 2015). Artemisinin and its derivatives (ARTs) are the most potent antimalarial drugs to date (Chen, 2016; O'Neill et al., 2010; Tu, 2011), but their use is stymied by recrudescence rates as high as 60% (Codd et al., 2011; de Vries and Dien, 1996; Meshnick et al., 1996). Malaria recrudescence, defined as the reappearance of the original strain of the parasite after antimalarial medications, is considered as treatment failure (Shaukat et al., 2012). To minimize this problem, the World Health Organization recommends against monotherapy in favor of ART-based combination therapy (ACT). Nevertheless, recrudescence *P. falciparum* infections have still been reported (Ndounga et al., 2015; Yeka et al., 2005).

Most clinical antimalarials are schizonticidal drugs, targeting blood stage parasites that are responsible for the clinical symptoms associated with malaria. Within blood cells,

merozoites develop to form either gametocytes or schizonts. *Plasmodium* schizonts release daughter merozoites and the free merozoites re-invade erythrocytes and differentiate into rings, trophozoites, and schizonts. Recrudescence following antimalarial therapy has been thought to occur as a result of drug-resistant parasites (O'Brien et al., 2011). However, recrudescence parasites isolated from patients remain sensitive to ARTs (Dondorp et al., 2009; Noedl et al., 2008; Phyo et al., 2012). As the *in vivo* half-life of ARTs is short (Li et al., 2014), it has been proposed that the concentration of the drug in plasma was insufficient to suppress all parasites (White, 2013). Consequently, longer courses of therapy or twice-a-day dosing intervals are recommended to efficiently clear the infection (Dogovski et al., 2015). Recent studies also indicate that ARTs induce transition of a subset of parasites into latent rings that are responsible for recrudescence (Codd et al., 2011; Grobler et al., 2014; LaCrue et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010). Despite its clinical importance, the molecular mechanism of ART-induced parasite latency remains unknown.

We have previously demonstrated that latent stages of apicomplexan parasites, including *Toxoplasma* and *Plasmodium*, coincide with increased phosphorylation of the α subunit of eukaryotic translation initiation factor-2 (eIF2), which delivers initiator tRNA to ribosomes. Phosphorylation of eIF2 α , which occurs during cellular stress, results in a reduction of general protein synthesis, accompanied by preferential translation of mRNAs encoding products that are important for recovery from the stress (Young and Wek, 2016). We hypothesized that translation control through parasite eIF2 α phosphorylation contributes to ART-induced latency. Consistent with this idea, RNA sequencing and microarray studies have shown that ribosomal protein genes are down-regulated in response to ART in the human malaria parasite, *P. falciparum*, and the rodent malaria parasite, *P. berghei* (Shaw et al., 2015). Furthermore, proteins involved in the translation process were among the most down-regulated gene products in ART-treated parasites (Shaw et al., 2015).

In *Plasmodium*, there are three eIF2 α kinases: eIK1, eIK2, and PK4 (Ward et al., 2004). The eIK1 protein kinase responds to amino acid deprivation during the erythrocytic stage (Babbitt et al., 2012; Fennell et al., 2009), while eIK2 controls sporozoite latency in the mosquito salivary glands (Zhang et al., 2010). Neither eIK1 nor eIK2 are essential for erythrocytic stage development (Fennell et al., 2009; Zhang et al., 2010). In contrast, PK4 phosphorylates eIF2 α in mature schizonts and is essential for parasite development in erythrocytes (Solyakov et al., 2011; Zhang et al., 2012a). In this study, we establish that eIF2 α phosphorylation by PK4 is critical for the ART-induced latency that leads to recrudescence and treatment failure. Importantly, small molecule inhibition of PK4 blocks the ability of the parasite transition into this latent phase and as a consequence prevents malaria recrudescence following ART treatment.

Results

ART induces eIF2 α phosphorylation in *Plasmodium*

Phosphorylation of eIF2 α has been associated with slow-growing and latent stages of parasite development (Babbitt et al., 2012; Fennell et al., 2009; Zhang et al., 2013; Zhang et al., 2012a). We sought to determine the status of eIF2 α phosphorylation in malaria parasites treated with ARTs as well as recrudescence parasites post-ART treatment. Two derivatives of

artemisinin have been employed to study malaria recrudescence: dihydroartemisinin (DHA) is used in cultured human malaria and artesunate (AS) in rodent malaria (Chen et al., 2014; Codd et al., 2011; LaCrue et al., 2011; Peatey et al., 2015; Shaw et al., 2015; Teuscher et al., 2012; Teuscher et al., 2010). We established recrudescence post-AS treatment in *P. berghei* ANKA infected Swiss Webster mice (Figure S1 and Table S1). Phosphorylation of *P. berghei* eIF2 α (PbIF2 α) was significantly enhanced following AS treatment and dephosphorylated in the recrudescence parasites (Figure 1A). Similar results were observed in *P. falciparum* cultures treated with DHA followed by magnetic column purification to remove parasites unaffected by DHA (Figure 1B) (Teuscher et al., 2010). High levels of *Plasmodium* eIF2 α phosphorylation in the small population (<1%, Figure S2) of latent parasites induced by ART were maintained with salubrinal (Sal) treatment, which has been established to inhibit the dephosphorylation of eIF2 α in multiple species, including apicomplexan parasites (Tsaytler and Bertolotti, 2013; Zhang et al., 2010) (Figure 1C). Addition of Sal to the latent parasites delayed parasite recrudescence in a dose-dependent manner (Figures 1D, 1E and S2). These results show that ARTs induce eIF2 α phosphorylation in *Plasmodium*, which is then removed in recrudescence parasites.

Parasites bearing phosphorylated eIF2 α are less sensitive to ART

Blood stage schizogony is a replicative process in which the parasite undergoes multiple rounds of nuclear division: ring stages differentiate to trophozoites and then mature into schizonts, which rupture and release merozoites. Free merozoites invade other erythrocytes to continue the asexual blood-stages of the life cycle. Phosphorylation of *Plasmodium* eIF2 α was not detectable in rings or trophozoites, but was observed in late schizonts (Figures 2A and B), consistent with the diminished protein synthesis seen in late schizonts (Fang et al., 2014; Zhang et al., 2012a). Schizonts bearing enhanced levels of phosphorylated eIF2 α were associated with high rates of recrudescence following ART treatment (Figures 2C and D). The level of eIF2 α phosphorylation was significantly enhanced in rings in response to ART treatment (Figures 2A and B). Recrudescence occurred in ring stages following ART treatment compared with trophozoites (Figures 2C and D). Thus, ARTs induce ring-stage parasites to increase the levels of phosphorylated eIF2 α and ring-stage parasites are less sensitive to ARTs.

Inclusion of Sal in either *P. berghei* or *P. falciparum* cultures increases the amount of eIF2 α phosphorylation (Figures 2E and F). Enhanced *Plasmodium* eIF2 α phosphorylation coincided with the parasites being less sensitive to ART treatment (Figures 2G and H), suggesting that translational control has a protective effect against the drug. Recrudescence following AS exposure occurred in all mice pretreated with Sal, compared to a 20–40% recrudescence rate in control groups with only basal levels of PbIF2 α phosphorylation. In addition, recrudescence occurred earlier in some mice pretreated with Sal. The earlier recrudescence following ART treatment was also observed in *P. falciparum* cultures pretreated with Sal. These findings show that increased levels of phosphorylated eIF2 α protects parasites from ART treatment.

The effect of Sal on the parasite's recrudescence post ART therapy depends on the time of Sal delivery. In the scenario of adding Sal after ART therapy, recrudescence was postponed

(Figures 1D and E). The explanation for this finding is that the parasite transits to latency after ART therapy, and adding Sal to the latent parasite prolongs the latency by maintaining the eIF2 α phosphorylation level. In the scenario of adding Sal prior to ART therapy, the recrudescence occurred earlier and with higher rate (Figures 2G and H). The rationale for this observation is that pretreatment of Sal increases eIF2 α phosphorylation level and the parasite transits into latency before ART therapy. The latent parasite is tolerant to ART treatment.

ART exposure activates the ER-resident eIF2 α kinase, PK4

Three eIF2 α kinases have been identified in *Plasmodium*: eIK1, eIK2, and PK4 (Tewari et al., 2010; Ward et al., 2004). We determined whether parasites lacking each of these eIF2 α kinases exhibited a defect in recrudescence following ART treatment. Figure S3 shows our successful generation of *PbeIK1* (-) parasites, and our generation of *PbeIK2* (-) parasites was described earlier (Zhang et al., 2010). *PbeIK1* (-) and *PbeIK2* (-) parasites proliferated normally in erythrocytes (Figure S3C) and no defect was observed in the enhanced eIF2 α phosphorylation in response to AS treatment (Figure S4A). Moreover, mice infected with either *PbeIK1* (-) or *PbeIK2* (-) parasites and treated with 3 or 5 doses of AS showed the same degree of recrudescence as wild-type (Figures S4B and S4C). These results show that neither *PbeIK1* nor *PbeIK2* contributes to AS-induced latency.

Plasmodium PK4, which has been shown to be essential for the parasite (Solyakov et al., 2011; Tewari et al., 2010; Zhang et al., 2012a), is related to the human eIF2 α kinase, PERK. Like PERK, PK4 contains a predicted transmembrane domain situated upstream of its protein kinase domain (Figure 3A). Also like PERK (Harding et al., 1999), we found that PK4 localizes to the parasite endoplasmic reticulum (ER) (Figure 3B and S5) in a complex with the ER-resident chaperone BIP (Kumar et al., 1991) (Figure 3C). We previously verified that the kinase domain of PK4 is able to phosphorylate eIF2 α using an *in vitro* assay (Zhang et al., 2012a). Notably, this reaction required oligomerization via the fused GST domain for both eIF2 α phosphorylation and autophosphorylation of PK4 (Zhang et al., 2012a), which is consistent with the reported mechanism of PERK activation (Harding et al., 1999; Walter and Ron, 2011). Additionally, we show that endogenous PK4 oligomerized post DHA treatment (Figure 3D), supporting the idea that oligomerization of PK4 leads to enhanced phosphorylation of eIF2 α in response to AS in 15 min (Figures 2B). Of importance, ART treatment also led to displacement of BIP from PK4, which coincides with PK4 oligomerization/autophosphorylation, and eIF2 α phosphorylation, which are processes that are also important for activation of PERK. Taken together, the results indicate that *Plasmodium* ER-resident eIF2 α kinase PK4 phosphorylates eIF2 α in response to AS treatment using a mechanism of kinase activation that is analogous to PERK.

Expression of a dominant-negative form of PK4 blocks recrudescence

Since PK4 is essential (Zhang et al., 2012a), we used a dominant-negative strategy to study its role in AS-induced latency and recrudescence. A dominant-negative version of PK4 was created by mutating the autophosphorylation site in PbPK4, threonine-2436 (Zhang et al., 2010); the mutation ablated PK4 autophosphorylation and eIF2 α phosphorylation (Figure 4A). An episomal plasmid was engineered to express the T2436A PK4 mutant or a control

version containing a change to a synonymous threonine codon (wt). These plasmids were transfected into *P. berghei* schizonts, which were then inoculated into mice. It was previously shown that expression of a mutant version of PERK can oligomerize with endogenous wild-type kinase and lower eIF2 α (Ma et al., 2002). Six hours later when the parasites had developed into rings, *PK4* mRNA levels representing the endogenous, synonymous, and T2436A mutant were analyzed by qRT-PCR. The mRNA levels of T2436A *PK4* were 10-fold higher than that of endogenous *PK4* (Figure 4B). The mRNA levels of wild-type *PK4* in the parasites transfected with the synonymous *PK4* expression cassette were ~2-fold higher relative to the parasites transfected with empty vector. Similar results were also reported for the same mutated version of a related mammalian eIF2 α kinase (Romano et al., 1998). Overexpression of eIF2 α kinases inhibits translation and eukaryotic cell growth, but analogous expression of a mutant eIF2 α kinase lacking activity are tolerated and therefore can be expressed at higher levels. At the protein level, total PK4 was increased in synonymous and dominant-negative PK4 overexpressing parasites (Figure 4C). As expected, eIF2 α phosphorylation was increased in parasites expressing the synonymous PK4 mutation, and protein synthesis was inhibited in these parasites accordingly (Figure 4D). Conversely, levels of eIF2 α phosphorylation were decreased in parasites expressing the T2436A PK4 mutant (Figure 4C), with a corresponding alleviation of translational repression (Figure 4D). Recrudescence following ART treatment occurred earlier and at a higher rate in parasites transfected with the functional PK4 containing a synonymous codon change, whereas no recrudescence was observed in parasites transfected with dominant-negative version of PK4 (Figure 4E). These findings further support the model that interference with PK4-mediated eIF2 α phosphorylation blocks the ART-induced latency that leads to recrudescence infection.

Pharmacological inhibition of PK4 blocks parasite differentiation from trophozoites into schizonts and attenuates recrudescence

We used another approach to test whether PK4 inhibition blocks ART-induced latency. Parasites were treated with GSK2606414, an established inhibitor of PERK (Axten et al., 2012). We first confirmed that PK4 kinase activity was specifically inhibited by GSK2606414 *in vitro*, and that GSK2606414 had no effect on eIK1 or eIK2 (Figure S6A–C). We next measured the effect of GSK2606414 on *P. berghei*-infected mice and *P. falciparum* cultures. GSK2606414 inhibits eIF2 α phosphorylation in asynchronized parasites (Figures 5A and B). In the control groups, asynchronized parasites containing all stages showed schizonts bearing phosphorylated eIF2 α (Figures 2A, 2B, 5A, and 5B). GSK2606414 reversibly inhibited parasite development in erythrocytes (Figures 5C, 5D and S6D–F), consistent with previous findings that the phosphorylation of eIF2 α by PK4 is essential for the development of the parasite in the erythrocytic cycle (Solyakov et al., 2011; Zhang et al., 2012a). During GSK2606414 treatment, parasites entered the trophozoite stage but did not progress to schizogony (Figure 5E and S6E), which is consistent with our previous observation that PK4 phosphorylates eIF2 α in late schizonts (Zhang et al., 2012a). We conclude that the inhibition of eIF2 α phosphorylation by GSK2606414 disrupts parasite differentiation from trophozoites into schizonts.

We next addressed whether GSK2606414 could affect ART-induced latency and recrudescence by inhibiting the PK4-mediated eIF2 α phosphorylation that occurs in response to ART. The combination of ART and GSK2606414 abolished parasite recrudescence in *P. berghei*-infected mice and *P. falciparum* cultures (Figure 5F and G), suggesting that inhibition of PK4 restores parasite sensitivity to ART.

PfeIF2 α phosphorylation in the ART-resistant parasite Dd2^{C580Y}

A transcriptome survey of *P. falciparum* clinical isolates found that ART resistance is associated with increased expression of genes involved in the unfolded protein response (UPR) pathways and with arrest in rings (Mok et al., 2015). In mammalian cells, the UPR is a cellular stress response resulting in phosphorylation of eIF2 α . Phosphorylation of eIF2 α can promote mammalian cell survival under stress (Ron and Walter, 2007; Walter and Ron, 2011). We sought to determine the status of eIF2 α phosphorylation in the ART-resistant parasite Dd2^{C580Y} before and after DHA treatment. PfK13-propeller mutations, including C580Y, confer ART resistance in *P. falciparum* (Straimer et al., 2015). The ART-sensitive and chloroquine-resistant parasite line Dd2 was included as a control. PfeIF2 α was phosphorylated in the young ring-stage of the ART-resistant parasite Dd2^{C580Y}, but not in the young ring-stage of the ART-sensitive parasite Dd2 (Figure 6A). However, PfeIF2 α was dephosphorylated in late rings and trophozoites. The phosphorylation of eIF2 α in late schizont-stage was observed in both sensitive and resistant parasites. The ART-resistant parasite Dd2^{C580Y} remained in a state of decelerated development at ring stage in culture. At 40 hours, the ART-resistant parasite reached the late schizont-stage just like the sensitive parasite (Figure 6A). This is consistent with the phenotype of *ex-vivo* culture of clinical ART-resistant isolates (Mok et al., 2015). Nevertheless, DHA did not induce higher levels of PfeIF2 α phosphorylation in the ART-resistant parasite Dd2^{C580Y}, in contrast to that observed in the sensitive Dd2 (Figure 6B). GSK2606414 reduced ART resistance in the parasite Dd2^{C580Y} (Figure 6C). An explanation of these results is that PfeIF2 α is basally phosphorylated in the young rings of the ART-resistant parasite, likely by PK4, and the resistant parasite do not respond to DHA by phosphorylating eIF2 α compared to the ART-sensitive parasite.

Discussion

ARTs are a formidable weapon against malaria, but a small proportion of parasites become latent during treatment and later reemerge in a phenomenon known as recrudescence (Cheng et al., 2012; Codd et al., 2011; LaCrue et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010). These recrudescence parasite isolates are not drug-resistant, suggesting that disruption of latency could remedy the treatment failure (Dondorp et al., 2009; Noedl et al., 2008; Phyo et al., 2012). Our findings indicate that the *Plasmodium* eIF2 α kinase PK4 is localized to the parasite ER and is activated by oligomerization and autophosphorylation in response to ARTs. Activated PK4 phosphorylates eIF2 α and inhibits global protein synthesis, promoting latency and providing for an adaptive state that allows for the parasite to better manage the damage accrued upon exposure to ARTs. Attenuation of PK4 activity through expression of a dominant-negative PK4 or application of a PERK inhibitor was successful in curbing recrudescence infection.

ART contains an endoperoxide group that causes oxidative stress, which leads to parasite clearance (O'Neill et al., 2010). Upon entering parasites, ARTs have been reported to traffic to a wide variety of subcellular organelles, including the ER, food vacuole, mitochondrion and other membrane-bound organelles (Eckstein-Ludwig et al., 2003; Hartwig et al., 2009; Stocks et al., 2007; Wang et al., 2010) and result in protein damage (Chen et al., 2017). ARTs induce PK4 activation in the ER of ring stages, resulting in the phosphorylation of eIF2 α that promotes latency associated with recrudescence infection (Cheng et al., 2012; Codd et al., 2011; LaCrue et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010). Ring stage parasites respond to ARTs by phosphorylating eIF2 α (Figure 2), which is concordant with previous reports describing the induction of latent rings by ARTs (Grobler et al., 2014; LaCrue et al., 2011; O'Brien et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010; Tucker et al., 2012; Witkowski et al., 2010).

In response to diverse stress stimuli, eukaryotic cells activate an adaptive pathway termed the integrated stress response (ISR) to restore cellular homeostasis. The ISR centers on the ability of cells to modulate translation of mRNAs through the phosphorylation of eIF2 α . Severe or prolonged stress will overwhelm the capacity of the adaptive response and initiate cell death (Pakos-Zebrucka et al., 2016). *Plasmodium* activates the parasitic ISR by phosphorylating eIF2 α in response to diverse cell perturbations, including stress induced by drugs such as ART or chloroquine (Suroliya and Padmanaban, 1991), or amino acid deprivation (Babbitt et al., 2012; Fennell et al., 2009). The percentage of parasites that retreat into a latent state during ART treatment depends on the initial parasitemia and drug dosage (Klonis et al., 2013; Teuscher et al., 2012). Longer courses of therapy or shorter intervals (e.g., twice daily regimen) are recommended to efficiently clear parasite infections (Dogovski et al., 2015). The recrudescence rate of a twice-daily regimen was lower than a once-daily regimen (Figure S1).

Recrudescence has also been reported to occur during monotherapy with other first-line antimalarial drugs (Bennett et al., 2013; Happi et al., 2004; Kugasia et al., 2014). Some clinical drugs have less inhibitory effect on schizonts compared with trophozoites (Table 1). Of interest, *Plasmodium* eIF2 α is basally phosphorylated in schizonts (Figures 2A and B), which likely explains their decreased sensitivity to drugs, including ART therapy (Klonis et al., 2013; LaCrue et al., 2011; Sullivan, 2013). The median lethal dose (LD₅₀) of DHA in the parasite rings and late schizonts is higher than that of trophozoites (Klonis et al., 2013; Sullivan, 2013). Latency induced by eIF2 α phosphorylation during the schizont stage may be triggered by the depletion of hemoglobin from host erythrocytes, leading to nutritional deprivation. The decreased drug sensitivity in the schizonts indicates that latency triggered by an underlying stress is accompanied by activation of an eIF2 α kinase which provides the parasite protection against a subsequent stresses, including those caused by drug exposure. This pre-conditioning mechanism affords the parasite an adaptive strategy that also helps to explain previous findings that *Plasmodium* preferentially progress to arrest as schizonts in response to antimalarials (Wilson et al., 2013). Consistent with this idea, augmentation of eIF2 α phosphorylation by virtue of Sal increased recrudescence rates to 100% (Figure 2G). Additional mechanisms may also contribute to schizonts being less sensitive to some drugs. Clearly, the role of *Plasmodium* eIF2 α phosphorylation in response to other clinical antimalarial drugs requires further investigation.

As proof of concept, we tested the PERK inhibitor, GSK2606414, on *Plasmodium* PK4 and subsequently malaria infection models. GSK2606414 inhibited PK4 alone, with no effect on the other two *Plasmodium* eIF2 α kinases that respond to alternative stress signals (Figure S6). Importantly, GSK2606414 inhibited *Plasmodium* eIF2 α phosphorylation and abolished recrudescence post-ART therapy (Figure 5). Since the ER, and hence PERK, are absent in mature erythrocytes, GSK2606414 is most likely exerting its activity through the parasite. In agreement with the PERK inhibitor study, over-expression of a mutated PK4 lacking eIF2 α kinase activity also inhibited recrudescence (Figure 4). Together, these results show that interference with the PK4-mediated stress response pathway offers a means to resolve the clinical problem of recrudescence infection.

In addition to recrudescence that has been reported decades ago (Li et al., 1984), the emergence and spread of ART resistance in recent years threatens malaria control and global public health (Dondorp et al., 2009). A transcriptome survey of *P. falciparum* clinical isolates found that ART resistance is associated with increased expression of genes in the unfolded protein response (UPR) (Mok et al., 2015). In mammalian cells, the UPR is a cellular stress response that is regulated by phosphorylation of eIF2 α (Ron and Walter, 2007; Walter and Ron, 2011). Lowered global protein synthesis controlled through PfeIF2 α phosphorylation could explain slow growth in the young rings of ART-resistant parasites (Mok et al., 2015) (Figure 6A). The young rings of ART-resistant parasite Dd2^{C580Y} are latent, and the phosphorylation levels of PfeIF2 α were not changed in response to 700 nM DHA treatment for 15 min by (Figure 6B). PfeIF2 α phosphorylation level in different erythrocytic stages of clinical isolates post longer time ART treatment requires further investigation. In higher eukaryotic cells, basal phosphorylation of eIF2 α is responsible for resistance to stress induced cell death (Zeng et al., 2011). Phosphorylation of PfeIF2 α may be responsible for resistance to ARTs. The eIF2 α kinase responsible for PfeIF2 α phosphorylation in ART-resistant parasites has not yet been identified. As PERK appears to be the only UPR responder conserved in *Apicomplexa*, it makes for a highly attractive drug target. PK4 is homologous to the human eIF2 α kinase PERK, and essential for the parasite erythrocytic cycle (Solyakov et al., 2011; Zhang et al., 2012a). Nevertheless, GSK2606414 reversibly inhibits the parasite differentiation into schizont and does not kill the parasite (Figure 5D,E and S6D–F). This result is consistent with the previous finding that the barcode of the PK4 mutant was still detected in the mouse 4–8 days post transfection of PK4 knockout plasmid (Gomes et al., 2015). The PK4 inhibitor GSK2606414 reduced ART resistance in Dd2^{C580Y} (Figure 6C), and PK4 may be responsible for phosphorylating PfeIF2 α in the ART-resistant parasite. Further investigation into the translational control, including genetically validating the PfeIF2 α kinase, in ART-resistant parasites may reveal additional ways to interfere with this critical pathway.

It has been reported that *P. falciparum* phosphatidylinositol-3-kinase (PfPI3K) and its lipid product phosphatidylinositol-3-phosphate (PI3P) are increased in ART-resistant parasites, and PI3P is the key mediator of ART resistance (Mbengue et al., 2015). It is of interest to investigate the relationship between the PfPI3K/PI3P and PfPK4/PfeIF2 α pathways using the PfPK4 inhibitor GSK2606414.

The discovery that translational control is critical for parasite recrudescence has far-reaching implications for other parasites with latent stages relevant to pathogenesis, such as *Toxoplasma gondii*. *Toxoplasma* is currently incurable because treatment of the replicative stage is believed to drive a subset of parasites back into the latent tissue cyst stage. It would be worthwhile to determine whether disruption of eIF2 α phosphorylation during drug treatment of toxoplasmosis prevents the formation of additional tissue cysts.

STAR METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti- <i>Plasmodium</i> eIF2 α -P	William J. Sullivan, Jr	(Narasimhan et al., 2008b)
Anti-total <i>Plasmodium</i> eIF2 α	William J. Sullivan, Jr	(Sullivan et al., 2004)
Anti- <i>Plasmodium</i> PK4	This paper	N/A
Anti- <i>Plasmodium</i> BIP	Nirbhay Kumar	(Kumar et al., 1991)
Parasites		
<i>P. berghei</i> ANKA	NYU Insectary Core Facility and Parasite Culture	https://med.nyu.edu/microbiology-parasitology/research/parasitology/insectary-core-facility-and-parasite-culture
<i>P. falciparum</i> 3D7	NYU Insectary Core Facility and Parasite Culture	https://med.nyu.edu/microbiology-parasitology/research/parasitology/insectary-core-facility-and-parasite-culture
<i>P. falciparum</i> Dd2	David Fidock	(Straimer et al., 2015)
<i>P. falciparum</i> Dd2 ^{C580Y}	David Fidock	(Straimer et al., 2015)
<i>PbeIK1</i> (-)	This paper	Figure S3
<i>PbeIK2</i> (-)	Victor Nussenzweig	(Zhang et al., 2010)
Chemicals, Peptides, and Recombinant Proteins		
Artesunate	Tokyo Chemical Industries Co. Ltd.	Cat#A2191
Dihydroartemisinin	AK Scientific, Inc.	Cat#K453
Salubrinol	Tocris Bioscience	Cat#2347
GSK2606414	MedChemexpress	Cat#HY-18072
Amodiaquin	Sigma-Aldrich	Cat#1031004
Atovaquone	Sigma-Aldrich	Cat#A7986
Pyrimethamine	Sigma-Aldrich	Cat#46706
Primaquine	Sigma-Aldrich	Cat# 1561507
Recombinant Protein GST-PbPK4KD T2436A mutant	This paper	N/A
Recombinant Protein GST-PfPK4KD	This paper	N/A
Recombinant Protein GST-PfeIK1KD	This paper	N/A
Recombinant Protein GST-PfeIK2KD	This paper	N/A
Recombinant Protein PfeIF2 α -His	This paper	N/A
Experimental Models: Cell Lines		
Human red blood cells	Interstate Blood Bank	http://www.interstatebloodbank.com/products.asp
Experimental Models: Organisms/Strains		
Mouse Swiss Webster	Taconic Biosciences	Tac:SW
Oligonucleotides		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
wt PbPK4 qPCR caaatgattgaacccctggatataca	This paper	N/A
synonymous PbPK4 qPCR cagatgtaggtacgccaggttacact	This paper	N/A
PbPK4 T2436A mutant qPCR cagatgtaggtgcaccaggttacact	This paper	N/A
PbArgRS qPCR	Eurofins	(Zhang et al., 2010)
Recombinant DNA		
plasmid pBC_PbeIK1KO	This paper	N/A
plasmid pGST-PfeIK1KD	This paper	N/A
plasmid pGST-PfeIK2KD	This paper	N/A
plasmid pGST-PfePK4KD	This paper	N/A
plasmid pPfeIF2 α -His	This paper	N/A
plasmid pPK4wt episome	This paper	N/A
plasmid pPK4T2436A episome	This paper	N/A
plasmid pVector episome	This paper	N/A
Software and Algorithms		
DNASTAR	DNASTAR, Inc.	https://www.dnastar.com/
Applied Biosystems 7500 Fast Real-Time PCR System	Applied Biosystems	http://www.appliedbiosystems.com/absite/us/en/home/support/software/real-time-pcr/ab-7500.html
Prism	GraphPad Software, Inc.	https://www.graphpad.com/

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Min Zhang (zhanmin@iu.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animal model—All animal work has been conducted according to Institutional Animal Care and Use Committee (IACUC) Laboratory Animal Protocol: 140102. Six-eight week old female Swiss Webster mice from Taconic Biosciences (genetics: recessive mutation *Pde6b*^{rd1}) were used in this study. All animals were housed at New York University Medical Center animal facilities under the care of the Division of Laboratory Animal Resources veterinary staff.

Human cells—Human red blood cells from O+ Caucasian donors were purchased from Interstate Blood Bank with authentication. All work on *P. falciparum* has been conducted according to Institutional Biosafety Committee protocols 16-000072 and IN-777. *P. falciparum* infected red blood cells were cultured in RPMI-based medium containing 5 mM glucose, 25 mM HEPES, 2 g/L NaHCO₃, 100 μ M hypoxanthine, 50 μ g/L gentamicin and 5% Albumax II, pH 7.2 at 37 °C in a mixture of nitrogen (90%), CO₂ (5%) and Oxygen (5%).

METHODS DETAILS

Drugs—Artesunate (AS) used in this study was obtained from Tokyo Chemical Industries Co. Ltd. The AS powder was dissolved in ethanol to make a 21 mg/mL stock, which was

further diluted with water to the administrated concentration and immediately introduced into the stomach of mice with an oral gavage cannula at 64 mg/kg mouse body weight as previously described (LaCrue et al., 2011). Dihydroartemisinin (DHA) used in this study was obtained from AK Scientific, Inc. DHA was dissolved in DMSO to make a 1 mM stock. *P. falciparum* 3D7 culture was treated with 200 nM DHA for 6 hours, followed by magnetic column purification for 3 consecutive days to remove unaffected parasites by the drug as previously described (Teuscher et al., 2010). The *in vivo* half-lives of AS and DHA are within one hour (O'Neill et al., 2010). Sal was obtained from Tocris bioscience and prepared as a 100 mM stock solution in DMSO. *P. berghei* infected mice were intravenously injected with Sal at 2 mg/kg mouse body weight. *P. falciparum* culture was treated with Sal at 10 μ M. The half-life of Sal in plasma is approximately 6 hours (Zhang et al., 2012b). GSK2606414 was obtained from MedChemexpress and prepared as a 100 mg/mL stock solution in DMSO. *P. berghei* infected mice were i.v. injected with 75 mg/kg of GSK2606414 in a solution with 0.5% hydroxypropyl methylcellulose and 0.1% Tween 80. *P. falciparum* culture was treated with GSK2606414 at 2 μ M.

Giemsa stain to monitor recrudescence—Thin blood smears were made from *P. berghei* infected mice and *P. falciparum* culture, followed by 100% methanol fixation and 1:10 diluted Giemsa solution for 10 min. Parasitemia were calculated by counting the normal erythrocytic stages, including replicative rings, trophozoites and schizonts.

Parasite purification and SDS-PAGE—After 3 doses of 64mg/kg AS treatment, *P. berghei* parasitized mouse blood was collected and the blood cells were washed twice in RPMI 1640. Then the red blood cells were collected after separation by Histopaque-1077 gradient centrifugation. Collected mouse red blood cells were then lysed with 0.2 % (w/v) saponin in PBS to released parasites. Parasite pellets were lysed and resuspended in SDS-PAGE loading buffer. Parasite proteins were resolved by SDS-PAGE and transferred to PVDF membrane for immunoblot. *P. falciparum* infected human red blood cells were treated with 200 nM DHA for 6 hours, followed by magnetic 3-step column purification to remove unaffected parasites by the drug (Teuscher et al., 2010).

Antiserum—The C-terminus of PK4 (outside of the kinase domain) fused with GST was expressed in *E. coli*, and the purified protein was used to immunize BALB/c mice. Immunoblot of *P. berghei* parasite lysates with the mouse serum (1:3,000 dilution) revealed a major band >290 kDa (endogenous PbPK4 is 310 kDa). PfbIP is a major ER chaperone protein (Kumar et al., 1991). The rabbit anti-PfbIP serum that was generated by immunization with a polypeptide consisting of the the last 11 amino acid residues of PfbIP was used to detect PbBIP (Kumar et al., 1991). This portion of BIP is highly conserved among the *Plasmodium* species (Roobsoong et al., 2014). The anti-total eIF2 α and anti-eIF2 α -P sera were generated in the laboratory of William J. Sullivan Jr., and used in *Plasmodium* as previously described (Narasimhan et al., 2008a; Zhang et al., 2010; Zhang et al., 2016).

Generation of *PbeIK1(-)* parasites—*PbeIK1* knockouts were generated using the same method that we previously described for generation of *PbeIK2 (-)* parasites (Zhang et al.,

2010). The 3'-terminal of *PbeIK1* coding sequence in the genome (PbANKA_130840, 4.5kb) is adjacent (less than 500 bp) to PbANKA_130830. We deleted the 5'-terminus (2.5-kb) of the *PbeIK1* coding sequence to avoid interference with the downstream gene. The 2.5-kb of the 5'-portion of this gene encodes the entire eIF2 α kinase catalytic domain (Zhang et al., 2010).

Overexpression of dominant-negative or wt PK4—The PbPK4 expression cassette contains 1.2-kb of the 5'-untranslated region (UTR), *PbPK4* coding sequence, and 1.0-kb of the 3'-UTR. The sequence around the threonine 2436 in endogenous *PbPK4* is caaatgattggaaccctggatataca (T2436 underlined); the sequence around the threonine 2436 in synonymous version of *PbPK4* is **cgatgataggt**accg**aggttact** (T2436 underlined, and synonymous mutations marked in bold); the *PbPK4* sequence with the alanine 2436 codon mutant is **cgatgataggt**gca**accg****aggttact** (A2436 underlined, and mutations marked in bold). Vector pUC57 encoding *PbPK4* with the synonymous or T2436A codons were transfected into *P. berghei* ANKA mature schizonts as previously described (Janse et al., 2006). Empty vector was a control. The transfected schizonts were intravenously injected to mice. Six hour later when the parasites developed into ring stage, the recipient mice were used to analyze *PK4* mRNA level, total PK4 protein level, eIF2 α phosphorylation level, and protein synthesis.

In Vitro kinase Assay—GST-tagged PfPK4 kinase domain was expressed and purified from *E. coli*. The purified GST-PfPK4KD and PbeIF2 α were incubated with 20 μ Ci [γ -³²P]ATP in a final concentration of 50 μ M and kinase buffer solution (15 mM Hepes [pH 7.5], 100 mM NaCl, 2 mM TCEP, 5 mM MgCl₂) in a volume of 50 μ L at 37 °C for 5–60 min. The GST-PfPK4KD protein was pre-incubated with GSK2606414, and PbeIF2 α and [γ -³²P]ATP were added. Proteins were then separated by SDS-PAGE, followed by autoradiography.

Glycerol-gradient sedimentation—The lysis buffer (1% Triton x 100, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 20 mM Hepes [pH 7.5]) was used to extract *Plasmodium* membrane proteins. Extracts were centrifuged through 20–40% glycerol gradients in polyallomer tubes of 11X 60 mm as described for the human eIF2 α kinase PERK (Bertolotti et al., 2000; Ma et al., 2002). Each 4-mL gradient was divided into eight equal fractions of 500 μ L. Aliquots of each fraction were subjected to SDS-PAGE after adjustment of the glycerol concentration in each fraction to 20%, and the contents of PK4 and BIP were measured by immunoblots.

Quantification and Statistical Analysis

***P. berghei* recrudescence in mouse:** Five Swiss Webster mice per group were used to monitor parasitemia of *P. berghei* in Figure 1D, 2C, 2G, 4E, 5C, 5D, and 5F. Ten Swiss Webster mice per group were used to monitor parasitemia of *P. berghei* in Figure S1, S3C, S4B and S4C.

Giesma stains, immunoblots, immunofluorescence assay, and *P. falciparum*

recrudescence assay: Three independent experiments were performed to confirm the reproducibility, and data are representative of 3 independent experiments.

The mRNA levels of *PK4* and incorporation of [³⁵S]Met/Cys: Two independent experiments were performed to evaluate the mRNA levels of *PK4* and the incorporation of [³⁵S]Met/Cys. Each value is the mean ± standard deviation (SD) of independent experiments (Figure 4B and 4D).

RSA survival rate: Five independent experiments were performed to evaluate RSA survival rate (Figure 6C). The normality assumption was tested using the Shapiro-Wilk test. Statistically significant differences were determined by the Student's t-test.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by grants from the National Institutes of Health (AI108592 to Victor Nussenzweig, AI124723 to WJS and RCW, AI070258 to MT). We thank Chandy John at Indiana University School of Medicine for providing laboratory facilities. We thank David Fidock at Columbia University for providing the parasites Dd2 and Dd2C580Y.

References

- Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, et al. Discovery of 7-methyl-5-(1-([3-(trifluoromethyl)phenyl]acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrido[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). *J Med Chem.* 2012; 55:7193–7207. [PubMed: 22827572]
- Babbitt SE, Altenhofen L, Cobbold SA, Istvan ES, Fennell C, Doerig C, Llinas M, Goldberg DE. *Plasmodium falciparum* responds to amino acid starvation by entering into a hibernatory state. *Proc Natl Acad Sci U S A.* 2012; 109:E3278–3287. [PubMed: 23112171]
- Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. Primaquine failure and cytochrome P-450 2D6 in *Plasmodium vivax* malaria. *N Engl J Med.* 2013; 369:1381–1382. [PubMed: 24088113]
- Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol.* 2000; 2:326–332. [PubMed: 10854322]
- Chen MZ, Moily NS, Bridgford JL, Wood RJ, Radwan M, Smith TA, Song Z, Tang BZ, Tilley L, Xu X, et al. A thiol probe for measuring unfolded protein load and proteostasis in cells. *Nat Commun.* 2017; 8:474. [PubMed: 28883394]
- Chen N, LaCrue AN, Teuscher F, Waters NC, Gatton ML, Kyle DE, Cheng Q. Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of *Plasmodium falciparum*. *Antimicrob Agents Chemother.* 2014; 58:4773–4781. [PubMed: 24913167]
- Chen WJ. Honoring antiparasitics: The 2015 Nobel Prize in Physiology or Medicine. *Biomed J.* 2016; 39:93–97. [PubMed: 27372164]
- Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in *Plasmodium falciparum*: A process linked to dormancy? *Int J Parasitol Drugs Drug Resist.* 2012; 2:249–255. [PubMed: 23420506]
- Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. *Malar J.* 2011; 10:56. [PubMed: 21385409]

- de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. *Drugs*. 1996; 52:818–836. [PubMed: 8957153]
- Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, Chotivanich K, Kenny S, Gnading N, Straimer J, et al. Targeting the cell stress response of *Plasmodium falciparum* to overcome artemisinin resistance. *PLoS Biol*. 2015; 13:e1002132. [PubMed: 25901609]
- Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, et al. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009; 361:455–467. [PubMed: 19641202]
- Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S. Artemisinins target the SERCA of *Plasmodium falciparum*. *Nature*. 2003; 424:957–961. [PubMed: 12931192]
- Fang X, Reifman J, Wallqvist A. Modeling metabolism and stage-specific growth of *Plasmodium falciparum* HB3 during the intraerythrocytic developmental cycle. *Mol Biosyst*. 2014; 10:2526–2537. [PubMed: 25001103]
- Fennell C, Babbitt S, Russo I, Wilkes J, Ranford-Cartwright L, Goldberg DE, Doerig C. PfeIK1, a eukaryotic initiation factor 2alpha kinase of the human malaria parasite *Plasmodium falciparum*, regulates stress-response to amino-acid starvation. *Malar J*. 2009; 8:99. [PubMed: 19435497]
- Gomes AR, Bushell E, Schwach F, Girling G, Anar B, Quail MA, Herd C, Pfander C, Modrzynska K, Rayner JC, et al. A genome-scale vector resource enables high-throughput reverse genetic screening in a malaria parasite. *Cell Host Microbe*. 2015; 17:404–413. [PubMed: 25732065]
- Grobler L, Chavchich M, Haynes RK, Edstein MD, Grobler AF. Assessment of the induction of dormant ring stages in *Plasmodium falciparum* parasites by artemisone and artemisone entrapped in Pheroid vesicles in vitro. *Antimicrob Agents Chemother*. 2014; 58:7579–7582. [PubMed: 25288088]
- Happi CT, Gbotosho GO, Sowunmi A, Falade CO, Akinboye DO, Gerena L, Kyle DE, Milhous W, Wirth DF, Oduola AM. Molecular analysis of *Plasmodium falciparum* recrudescence malaria infections in children treated with chloroquine in Nigeria. *Am J Trop Med Hyg*. 2004; 70:20–26. [PubMed: 14971693]
- Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature*. 1999; 397:271–274. [PubMed: 9930704]
- Hartwig CL, Rosenthal AS, D'Angelo J, Griffin CE, Posner GH, Cooper RA. Accumulation of artemisinin trioxane derivatives within neutral lipids of *Plasmodium falciparum* malaria parasites is endoperoxide-dependent. *Biochem Pharmacol*. 2009; 77:322–336. [PubMed: 19022224]
- Janse CJ, Ramesar J, Waters AP. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite *Plasmodium berghei*. *Nat Protoc*. 2006; 1:346–356. [PubMed: 17406255]
- Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. *Proc Natl Acad Sci U S A*. 2013; 110:5157–5162. [PubMed: 23431146]
- Kugasia IR, Polara FK, Assallum H. Recrudescence of *Plasmodium malariae* after Quinine. *Case Rep Med*. 2014; 2014:590265. [PubMed: 24711818]
- Kumar N, Koski G, Harada M, Aikawa M, Zheng H. Induction and localization of *Plasmodium falciparum* stress proteins related to the heat shock protein 70 family. *Mol Biochem Parasitol*. 1991; 48:47–58. [PubMed: 1779989]
- LaCrue AN, Scheel M, Kennedy K, Kumar N, Kyle DE. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model *Plasmodium vinckei*. *PLoS One*. 2011; 6:e26689. [PubMed: 22039533]
- Li GQ, Arnold K, Guo XB, Jian HX, Fu LC. Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. *Lancet*. 1984; 2:1360–1361. [PubMed: 6150365]
- Li Q, Remich S, Miller SR, Ogutu B, Otieno W, Melendez V, Teja-Isavadharm P, Weina PJ, Hickman MR, Smith B, et al. Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. *Malar J*. 2014; 13:281. [PubMed: 25047305]

- Ma K, Vattem KM, Wek RC. Dimerization and release of molecular chaperone inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response to endoplasmic reticulum stress. *J Biol Chem.* 2002; 277:18728–18735. [PubMed: 11907036]
- Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, et al. A molecular mechanism of artemisinin resistance in *Plasmodium falciparum* malaria. *Nature.* 2015; 520:683–687. [PubMed: 25874676]
- Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. *Microbiol Rev.* 1996; 60:301–315. [PubMed: 8801435]
- Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, Chotivanich K, Imwong M, Pukrittayakamee S, Dhorda M, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. *Science.* 2015; 347:431–435. [PubMed: 25502316]
- Narasimhan J, Joyce BR, Naguleswaran A, Smith AT, Livingston MR, Dixon SE, Coppens I, Wek RC, Sullivan WJ Jr. Translation Regulation by Eukaryotic Initiation Factor-2 Kinases in the Development of Latent Cysts in *Toxoplasma gondii*. *J Biol Chem.* 2008a; 283:16591–16601. [PubMed: 18420584]
- Narasimhan J, Joyce BR, Naguleswaran A, Smith AT, Livingston MR, Dixon SE, Coppens I, Wek RC, Sullivan WJ Jr. Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in *Toxoplasma gondii*. *J Biol Chem.* 2008b; 283:16591–16601. [PubMed: 18420584]
- Ndonga M, Pembe Issamou M, Casimiro PN, Koukouikila-Koussounda F, Bitemo M, Diassivy Matondo B, Ndonga Diakou LA, Basco LK, Ntoumi F. Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study. *Malar J.* 2015; 14:423. [PubMed: 26511848]
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med.* 2008; 359:2619–2620. [PubMed: 19064625]
- O'Brien C, Henrich PP, Passi N, Fidock DA. Recent clinical and molecular insights into emerging artemisinin resistance in *Plasmodium falciparum*. *Curr Opin Infect Dis.* 2011; 24:570–577. [PubMed: 22001944]
- O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin--the debate continues. *Molecules.* 2010; 15:1705–1721. [PubMed: 20336009]
- Pakos-Zebrucka K, Koryga I, Mnich K, Ljubic M, Samali A, Gorman AM. The integrated stress response. *Embo Rep.* 2016; 17:1374–1395. [PubMed: 27629041]
- Peatey CL, Chavchich M, Chen N, Gresty KJ, Gray KA, Gatton ML, Waters NC, Cheng Q. Mitochondrial Membrane Potential in a Small Subset of Artemisinin-Induced Dormant *Plasmodium falciparum* Parasites In Vitro. *J Infect Dis.* 2015; 212:426–434. [PubMed: 25635122]
- Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet.* 2012; 379:1960–1966. [PubMed: 22484134]
- Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhlen K, Nagle A, Adrian F, Matzen JT, Anderson P, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. *Proc Natl Acad Sci U S A.* 2008; 105:9059–9064. [PubMed: 18579783]
- Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, Herring C, Mathews MB, Qin J, Hinnebusch AG. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. *Mol Cell Biol.* 1998; 18:2282–2297. [PubMed: 9528799]
- Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol.* 2007; 8:519–529. [PubMed: 17565364]
- Roobsoong W, Maher SP, Rachaphaew N, Barnes SJ, Williamson KC, Sattabongkot J, Adams JH. A rapid sensitive, flow cytometry-based method for the detection of *Plasmodium vivax* 490 infected blood cells. *Malar J.* 2014; 13:55. [PubMed: 24528780]

- Shaukat AM, Gilliams EA, Kenefic LJ, Laurens MB, Dzinjalama FK, Nyirenda OM, Thesing PC, Jacob CG, Molyneux ME, Taylor TE, et al. Clinical manifestations of new versus recrudescence malaria infections following anti-malarial drug treatment. *Malar J.* 2012; 11:207. [PubMed: 22709627]
- Shaw PJ, Chaotheing S, Kaewprommal P, Piriyaopongsa J, Wongsombat C, Suwannakitti N, Koonyosying P, Uthaipibull C, Yuthavong Y, Kamchonwongpaisan S. Plasmodium parasites mount an arrest response to dihydroartemisinin, as revealed by whole transcriptome shotgun sequencing (RNA-seq) and microarray study. *BMC Genomics.* 2015; 16:830. [PubMed: 26490244]
- Solyakov L, Halbert J, Alam MM, Semblat JP, Dorin-Semblat D, Reininger L, Bottrill AR, Mistry S, Abdi A, Fennell C, et al. Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. *Nat Commun.* 2011; 2:565. [PubMed: 22127061]
- Stocks PA, Bray PG, Barton VE, Al-Helal M, Jones M, Araujo NC, Gibbons P, Ward SA, Hughes RH, Biagini GA, et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. *Angew Chem Int Ed Engl.* 2007; 46:6278–6283. [PubMed: 17640025]
- Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. *Science.* 2015; 347:428–431. [PubMed: 25502314]
- Sullivan DJ. Timing is everything for artemisinin action. *P Natl Acad Sci USA.* 2013; 110:4866–4867.
- Sullivan WJ Jr, Narasimhan J, Bhatti MM, Wek RC. Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control. *Biochem J.* 2004; 380:523–531. [PubMed: 14989696]
- Suroliya N, Padmanaban G. Chloroquine inhibits heme-dependent protein synthesis in Plasmodium falciparum. *Proc Natl Acad Sci U S A.* 1991; 88:4786–4790. [PubMed: 2052558]
- Teuscher F, Chen N, Kyle DE, Gatton ML, Cheng Q. Phenotypic changes in artemisinin-resistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. *Antimicrob Agents Chemother.* 2012; 56:428–431. [PubMed: 21986828]
- Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. *J Infect Dis.* 2010; 202:1362–1368. [PubMed: 20863228]
- Tewari R, Straschil U, Bateman A, Bohme U, Cherevach I, Gong P, Pain A, Billker O. The systematic functional analysis of Plasmodium protein kinases identifies essential regulators of mosquito transmission. *Cell Host Microbe.* 2010; 8:377–387. [PubMed: 20951971]
- Tsaytler P, Bertolotti A. Exploiting the selectivity of protein phosphatase 1 for pharmacological intervention. *FEBS J.* 2013; 280:766–770. [PubMed: 22340633]
- Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat Med.* 2011; 17:1217–1220. [PubMed: 21989013]
- Tucker MS, Mutka T, Sparks K, Patel J, Kyle DE. Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. *Antimicrob Agents Chemother.* 2012; 56:302–314. [PubMed: 22083467]
- Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. *Science.* 2011; 334:1081–1086. [PubMed: 22116877]
- Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, Zhou B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. *PLoS One.* 2010; 5:e9582. [PubMed: 20221395]
- Ward P, Equinet L, Packer J, Doerig C. Protein kinomes of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. *BMC Genomics.* 2004; 5:79. [PubMed: 15479470]
- White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. *Antimicrob Agents Chemother.* 2013; 57:5792–5807. [PubMed: 24002099]
- Wilson DW, Langer C, Goodman CD, McFadden GI, Beeson JG. Defining the timing of action of antimalarial drugs against Plasmodium falciparum. *Antimicrob Agents Chemother.* 2013; 57:1455–1467. [PubMed: 23318799]

- Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, Berry A, Benoit-Vical F. Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. *Antimicrob Agents Chemother.* 2010; 54:1872–1877. [PubMed: 20160056]
- World Health Organization. World malaria report. Geneva, Switzerland: World Health Organization; 2015.
- Yeka A, Banek K, Bakayaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsoby SL, Kilian A, Slater M, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. *Plos Med.* 2005; 2:e190. [PubMed: 16033307]
- Young SK, Wek RC. Upstream Open Reading Frames Differentially Regulate Gene-specific Translation in the Integrated Stress Response. *J Biol Chem.* 2016; 291:16927–16935. [PubMed: 27358398]
- Zeng N, Li Y, He L, Xu X, Galicia V, Deng C, Stiles BL. Adaptive basal phosphorylation of eIF2alpha is responsible for resistance to cellular stress-induced cell death in Pten-null hepatocytes. *Mol Cancer Res.* 2011; 9:1708–1717. [PubMed: 22009178]
- Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister S, Caspi A, Doerig C, Nussenzweig RS, Tuteja R, et al. The *Plasmodium* eukaryotic initiation factor-2alpha kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. *J Exp Med.* 2010; 207:1465–1474. [PubMed: 20584882]
- Zhang M, Joyce BR, Sullivan WJ Jr, Nussenzweig V. Translational control in *Plasmodium* and toxoplasma parasites. *Eukaryot Cell.* 2013; 12:161–167. [PubMed: 23243065]
- Zhang M, Mishra S, Sakthivel R, Fontoura BM, Nussenzweig V. UIS2: A Unique Phosphatase Required for the Development of *Plasmodium* Liver Stages. *PLoS Pathog.* 2016; 12:e1005370. [PubMed: 26735921]
- Zhang M, Mishra S, Sakthivel R, Rojas M, Ranjan R, Sullivan WJ Jr, Fontoura BM, Menard R, Dever TE, Nussenzweig V. PK4, a eukaryotic initiation factor 2alpha(eIF2alpha) kinase, is essential for the development of the erythrocytic cycle of *Plasmodium*. *Proc Natl Acad Sci U S A.* 2012a; 109:3956–3961. [PubMed: 22355110]
- Zhang P, Hamamura K, Jiang C, Zhao L, Yokota H. Salubrinal promotes healing of surgical wounds in rat femurs. *J Bone Miner Metab.* 2012b; 30:568–579. [PubMed: 22610062]

Highlights

- *Plasmodium* eIF2 α kinase PK4 is activated upon artemisinin treatment
- eIF2 α phosphorylation by PK4 leads to latency and recrudescence post artemisinin therapy
- Inhibiting PK4 abolishes recrudescence after artemisinin therapy




Figure 1. Phosphorylation of eIF2 α in response to ART treatment in *Plasmodium* parasites (A) *P. berghei* ANKA infected mice were treated with 3 doses of AS (64 mg/kg/dose, 12-hour interval), and AS-treated parasites were collected 6 hours after the final dose of AS. Parasite recrudescence 8 days post-AS treatment, and the recrudescence parasites were collected on day 8. The levels of phosphorylated PbeIF2 α (PbeIF2 α -P) and total PbeIF2 α were measured by immunoblot in the untreated, AS-treated and recrudescence parasites. (B) Asynchronous *P. falciparum* 3D7 culture was treated for 6 hours with 200 nM DHA followed by magnetic column purification to remove unaffected parasites by the drug. DHA-treated parasites were collected immediately after column purification. Parasite recrudescence 12 days post-DHA treatment, and the recrudescence parasites were collected on day 12. The untreated parasites without magnetic column purification were included as a control. Levels of PfeIF2 α -P and total PfeIF2 α in the untreated, DHA-treated, and recrudescence parasites were analyzed by immunoblot. (C) Mice infected with *P. berghei* ANKA were treated orally with 64 mg/kg AS. One day later, the normal erythrocytic stage parasites were undetectable by Giemsa stain and there was increased levels of phosphorylated PbeIF2 α (lane 1). The mice were then separated into 2 groups: mice in one group were i.v. injected with Sal (2mg/kg) and the other group was vehicle control. 24 hours after Sal administration, normal erythrocytic stage parasites recurred in the control group harboring dephosphorylated

PbeIF2 α (lane 2); recrudescence was undetectable in the Sal-treated mice and PbeIF2 α was phosphorylated (lane 3). Two days post-Sal treatment the parasites recrudescence and their PbeIF2 α was dephosphorylated (lane 4). **(D)** Sal prolongs AS-induced latency in *P. berghei* infected mice. One to five doses of AS were administered orally to the infected mice, then Sal was i.v. injected into mice on day 1 or on days 1–3 post-AS treatment. Giemsa stain (sensitivity of 0.01% parasitemia) was performed to determine recrudescence rate. **(E)** Sal prolongs DHA-induced latency in *P. falciparum* culture. DHA-treated *P. falciparum* 3D7 cultures followed by magnetic column purification were treated with 10 μ M Sal on day 2 or on days 2, 4, and 6 post-DHA treatment. Data are representative of 3 independent experiments. Related to Figure S1, S2 and Table S1.




Figure 2. Parasites bearing phosphorylated eIF2 α are less sensitive to ART

(A) Ring, trophozoite, and schizont stages of *P. berghei* ANKA were treated with 64 mg/kg AS for 15 min and levels of PbeIF2 α -P and total PbeIF2 α were determined by immunoblot. (B) Ring, trophozoite, and schizont stages of *P. falciparum* 3D7 were treated with 200 nM DHA for 15 min. Amounts of PfeIF2 α -P and total PfeIF2 α were determined by immunoblot. (C) Recrudescence of *P. berghei* rings, trophozoites, and schizonts following 3 doses of 64 mg/kg AS as determined by Giemsa stain. (D) Recrudescence of *P. falciparum* rings, trophozoites, and schizonts after a 6 hour treatment with 200 nM DHA treatment, followed by magnetic column purification to the unaffected parasites by DHA. (E) PbeIF2 α -P levels after pre-treatment with Sal. Mice infected with asynchronized *P. berghei* were intravenously injected with 2 mg/kg Sal 24 hours before AS treatment. PbeIF2 α -P levels were analyzed by immunoblots. (F) PfeIF2 α -P levels after pre-treatment with Sal. Asynchronized *P. falciparum* were treated with 10 μ M Sal for 2 hours. (G) Recrudescence rates of AS-treated *P. berghei* following increased levels of eIF2 α phosphorylation by Sal treatment. *P. berghei* infected mice were intravenously injected with Sal 24 hours before the mice were orally administered 3 or 5 doses of 64 mg/kg AS. (H) Recrudescence rates of DHA-treated *P. falciparum* 3D7 after inflating eIF2 α phosphorylation with Sal.

Asynchronized *P. falciparum* 3D7 were treated with Sal for 2 hours. The medium was then refreshed and the parasites were treated with 200 nM DHA for 6 hours, followed by a step of magnetic column purification to the unaffected parasites by DHA. Data are representative of 3 independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. ART treatment and PK4 activation

(A) A box represents the PK4 protein, with the luminal domain, transmembrane domain (TM), and eIF2 α kinase domain indicated, along with corresponding residue numbers. (B) Subcellular co-localization of PK4 (green) and BIP (red) as revealed by immunofluorescence in erythrocytic stages of *P. berghei*. DAPI (blue) was used as a co-stain to show the parasite nuclei. Scale bar, 10 μ m. (C) Whole cell extracts from *P. berghei* blood stage parasites untreated or treated with AS for 15 min were immediately subjected to immunoprecipitation (IP) with anti-PK4 or anti-BIP antibodies followed, by immunoblot (IB) analysis with the designated antibody. (D) PpPK4 oligomerizes in response to DHA. Left panel, contents of PK4 and BIP from lysates of untreated or 200 nM DHA-treated (15 min) *P. falciparum* 3D7 culture. Right panels, measurements of PK4 protein after size fractionation of lysates by sedimentation on a 20–40% glycerol gradient. The fractionation numbers are indicated and PK4 levels were measured in gradient fractions by immunoblot. Related to Figure S3, S4 and S5.




Figure 4. Effect of PK4 on parasite recrudescence following ART treatment

(A) A dominant-negative form of PK4 was created by mutating the autophosphorylation site (T2436A), which inhibits kinase activity *in vitro*. GST-tagged PbPK4KD wt or T2436A mutant proteins were incubated with PbeIF2 α and [γ -³²P] ATP. Samples were then resolved on SDS-PAGE for autoradiography. (B) The mRNA levels of *PK4* in *P. berghei* parasites harboring empty vector, episomal plasmid expressing functional *PK4* with a synonymous codon change or a version encoding the T2436A mutant. *P. berghei* ring stage parasites were analyzed for the levels of endogenous, synonymous, and T2436A mutant *PK4* mRNAs. The arginyl-tRNA synthetase (PbArgRS, PB000094.03.0) was used as internal control. Each value is the mean \pm standard deviation (SD) of two independent experiments. (C) Expression of dominant-negative PK4 inhibits phosphorylation of *P. berghei* eIF2 α . Levels of total PK4 protein, phosphorylated PbeIF2 α , and total PbeIF2 α in the parasites harboring the different episomes were revealed by immunoblotting. (D) Expression of dominant-negative PK4 enhances protein synthesis in the parasite. Protein synthesis was analyzed by incorporation of [³⁵S]Met/Cys. Each value is the mean \pm SD of two independent experiments. (E) Expression of dominant-negative PK4 abolishes recrudescence following AS treatment. Mice infected with *P. berghei* parasites harboring the three designated episomes were treated with 3 doses of 64 mg/kg AS. Data are representative of 3 independent experiments.




Figure 5. PK4 inhibitor GSK2606414 prevents recrudescence following ART treatment
 Effects of GSK2606414 on the levels of *Plasmodium* eIF2 α phosphorylation 24 hours after 75 mg/kg GSK2606414 treatment of mice infected with asynchronized *P. berghei* ANKA (A) and 48 hours after 2 μ M GSK2606414 treatment of asynchronized *P. falciparum* 3D7 parasites in culture (B). *Plasmodium* eIF2 α phosphorylation levels were evaluated by immunoblot. Parasitemia \pm SD of *P. berghei* ANKA infected mice (C) and *P. falciparum* 3D7 culture (D) treated with GSK2606414 were determined by microscopy after Giemsa stain. Arrows indicate the two days that GSK2606414 was added. (E) Giemsa stains of *P. falciparum* 3D7 culture treated with 2 μ M GSK2606414. DMSO-treated parasites complete the erythrocytic cycle in ~48 hours, in contrast to GSK2606414-treated parasites, which halt differentiation at the trophozoite stage. (F) Recrudescence of *P. berghei* after combination therapy. *P. berghei* infected mice were intravenously injected with 75 mg/kg Sal and 1 hr later were orally administered 3 or 5 doses of 64 mg/kg AS. Giemsa stain was performed to determine recrudescence rate. (G) Recrudescence of *P. falciparum* 3D7 in culture after combination therapy of GSK2606414 and DHA. Asynchronized *P. falciparum* 3D7 parasites were treated with 2 μ M GSK2606414 or DMSO for 1 hr, followed by a treatment of 200 nM DHA for 6 hrs. Data are representative of 3 independent experiments. Related to Figure S6.




Figure 6. Phosphorylation of PfeIF2α in a *PfK13* C580Y mutant parasite

(A) ART-resistant Dd2^{C580Y} and ART-sensitive Dd2 parasites collected at different hours post the incubation of late-stage schizonts and fresh red blood cells were subjected to immunoblot analysis of PfeIF2α-P and total PfeIF2α. R, ring; T, trophozoite; S, schizont.

(B) Young rings (0–3 hours post invasion of erythrocytes) of Dd2^{C580Y} and Dd2 were treated with 700 nM DHA for 15 min, and PfeIF2α phosphorylation levels were evaluated by immunoblot. Data are representative of 3 independent experiments.

(C) GSK2606414 reduced ART resistance. Young rings (0–3 h post invasion) of the ART-resistant parasite Dd2^{C580Y} and the ART-sensitive parasite Dd2 were pre-treated with 2 μM GSK2606414 for 2 h, and then the rings (2–5 h) were treated with a pulse of 700 nM DHA for 6 h. RSA survival rate ± SD of the parasite was measured. DMSO-treated parasites were used as controls. *P<0.05; #P>0.05. Data are representative of 5 independent experiments.

Table 1

Inhibition of *P. falciparum* 3D7 growth after 4 hour treatment with antimalarial drugs*.

Fluorescence (485/530 nm)	Concentration	Rings	Trophozoites	Schizonts
Amodiaquin	600 nM	5,801	5,065	93,628
Atovaquone	5 μ M	5,231	5,051	6,177
Pyrimethamine	4 μ M	5,579	5,477	84,981
Primaquine	1 μ M	102,496	6,900	67,726
DHA	200 nM	100,835	6,025	87,180
DMSO		155,341	154,326	155,253

* *P. falciparum* 3D7 0–3 h rings, 21–24 h trophozoites, and 32–35 h schizonts were simultaneously treated with a pulse of antimalarial drugs for 4 hours. DMSO-treated parasites maintained their ring, trophozoite, or schizont stages during the 4 hour treatment period. Parasites were washed and medium was refreshed after the 4-hour drug treatment. Ninety-six hours later, parasite load was evaluated by SYBR Green I nucleic acid staining dye (Plouffe et al., 2008). Data are representative of 3 independent experiments. Fluorescence emissions with >10% difference relative to trophozoites are marked in bold.